Femoden - Instructions For Use, Reviews, Price, Tablets, Pills

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Femoden

Femoden: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. For violations of liver function
11. 11. Use in the elderly
12. 12. Drug interactions
13. 13. Analogs
14. 14. Terms and conditions of storage
15. 15. Terms of dispensing from pharmacies
16. 16. Reviews
17. 17. Price in pharmacies

Latin name: Femoden

ATX code: G.03. AA10

Active ingredient: gestodene + ethinylestradiol (gestodene + ethinylestradiol)

Producer: Schering GmbH & Co. Productions KG (Germany), Jenafarm GmbH (Germany), Bayer Weimar GmbH & Co., KG (Germany)

Description and photo updated: 2018-26-11

Prices in pharmacies: from 680 rubles.

Buy

Femoden is a combined contraceptive drug (estrogen + gestagen).

Release form and composition

Dosage forms of Femoden:

• dragee: white, round (in blisters with a calendar scale, 21 pcs., in a cardboard box 1 blister);
• film-coated tablets: white, round (in blisters of 21 pcs., in a carton box of 1 or 3 blisters).

Composition of 1 dragee:

• active substances: gestodene - 0.075 mg, ethinylestradiol - 0.03 mg;
• auxiliary components: montanglycol wax, talc, calcium carbonate, polyethylene glycol 6000, polyvidone 700,000, magnesium stearate, sodium calcium edetate, polyvidone 25,000, corn starch, lactose.

Composition of 1 coated tablet:

• active substances: gestodene - 0.075 mg, ethinylestradiol - 0.03 mg;
• auxiliary components: magnesium stearate, sodium calcium edetate, povidone 25,000, corn starch, lactose monohydrate;
• shell: mountain wax glycolic, talc, calcium carbonate, macrogol 6000, povidone 700 000, sucrose.

Pharmacological properties

Pharmacodynamics

Femoden is a combined oral, low-dose, monophasic estrogen-gestagenic contraceptive. Its contraceptive effect is carried out through complementary mechanisms, the most important of which is a change in the state of the cervical secretion, due to which it becomes impenetrable for spermatozoa, and the suppression of ovulation.

In patients receiving combined oral contraceptives, there is a decrease in the intensity and soreness of menstrual bleeding and a more regular cycle, which reduces one of the risk factors for iron deficiency anemia. There is also evidence of a reduced risk of ovarian and endometrial cancer.

With the correct use of Femoden, the Pearl index is <1. An increase in the index is possible with the incorrect use of tablets / dragees, including when they are skipped.

Pharmacokinetics

Gestodene characteristic:

• absorption: quickly and completely absorbed after oral administration; C _max (maximum concentration in blood plasma) is 4 ng per 1 ml, is reached after approximately 1 hour; bioavailability is about 99%;
• distribution: binds to SHBG (sex hormone-binding globulin) and blood plasma albumin; 1–2% of the total concentration in blood plasma is in free form, from 50 to 70% - specifically associated with SHBG; the binding of gestodene to plasma proteins is influenced by the induction of SHBG synthesis by ethinyl estradiol;
• metabolism: almost completely metabolized; clearance from plasma is approximately 0.8 ml per kg per minute;
• elimination: the concentration of gestodene in plasma undergoes a two-phase decrease; the half-life (T _½) in the terminal phase varies from 12 to 15 hours; excreted only as metabolites by the kidneys and intestines in a ratio of about 6: 4 with a half-life of about 24 hours; not displayed unchanged;
• equilibrium concentration: the pharmacokinetics of gestodene is affected by the concentration of SHBG in the blood plasma; the concentration of the substance in plasma with daily intake increases 4 times during the second half of the contraceptive cycle.

Ethinyl estradiol characteristics:

• absorption: quickly and completely absorbed after oral administration; C _max is approximately 80 ng per ml and is achieved in 1-2 hours; metabolized during absorption and "primary passage" through the liver, due to which the bioavailability of the substance when taken orally is on average about 45%;
• distribution: approximately 98% (almost completely) nonspecifically binds to albumin; induces the synthesis of SHBG; the apparent volume of distribution (V _d) varies from 2.8 to 8.6 liters per 1 kg;
• metabolism: undergoes presystemic conjugation both in the liver and in the mucous membrane of the small intestine; the main metabolic pathway is aromatic hydroxylation; the rate of clearance from blood plasma is from 2.3 to 7 ml per 1 kg per minute;
• elimination: the decrease in the concentration of ethinyl estradiol in the blood plasma is biphasic; the first phase is characterized by T _½ about 1 hour, the second - from 10 to 20 hours; not excreted from the body unchanged; ethinyl estradiol metabolites are excreted through the kidneys and intestines in a ratio of 4: 6 with a half-life of about 24 hours;
• equilibrium concentration: reached after approximately 7 days.

Indications for use

According to the instructions, Femoden is prescribed for oral contraception.

Contraindications

Absolute:

• venous / arterial thrombosis and thromboembolism currently or in history, including myocardial infarction, pulmonary embolism, thrombophlebitis or deep vein thrombosis, hemorrhagic or ischemic cerebrovascular disorders;
• conditions preceding thrombosis at present or in history, including angina pectoris, transient ischemic attacks;
• identified predisposition to arterial or venous thrombosis, including antibodies to phospholipids (lupus anticoagulant, antibodies to cardiolipin), hyperhomocysteinemia, protein S and C deficiency, antithrombin III, resistance to activated protein C;
• uncontrolled hypertension;
• multiple or severe risk factors for arterial or venous thrombosis, including atrial fibrillation, extensive trauma, extended surgery with prolonged immobilization, subacute bacterial endocarditis, complicated lesions of the heart valve apparatus;
• migraine with focal neurological symptoms at present or in history;
• diabetes mellitus with diabetic angiopathy;
• pancreatitis with severe hypertriglyceridemia at present or in history;
• severe liver pathologies and liver failure (before normalization of liver function tests), including congenital hyperbilirubinemia (Rotor syndrome, Dubin-Johnson, Gilbert), jaundice;
• benign or malignant liver tumors currently or in history;
• identified hormone-dependent malignant neoplasms, including neoplasms of the mammary glands or genitals, or suspicion of them;
• bleeding from the vagina of an unclear nature;
• lactose / fructose intolerance, lactase, sucrase or isomaltase deficiency, glucose-galactose malabsorption;
• elderly age;
• pregnancy or suspicion of it;
• period of breastfeeding;
• individual intolerance to the components contained in Femoden.

Relative (diseases / conditions, in the presence of which the appointment of Femoden in the form of pills is currently possible after careful weighing of the alleged risks with the predicted benefits in each individual case):

• risk factors for the development of thrombosis and thromboembolism, including uncomplicated heart valve pathologies, migraine without focal neurological symptoms, arterial hypertension, dyslipoproteinemia, obesity, cerebrovascular accident or myocardial infarction at a young age in one of the closest relatives, thrombosis or a predisposition to them;
• other diseases, the presence of which can cause impaired peripheral circulation (phlebitis of superficial veins, sickle cell anemia, ulcerative colitis, Crohn's disease, hemolytic uremic syndrome, systemic lupus erythematosus, diabetes mellitus without vascular complications);
• hypertriglyceridemia;
• liver pathology with normal indicators of functional tests;
• diseases that first appeared or worsened during pregnancy or previous use of sex hormones (for example, Sydenham's chorea, herpes during pregnancy, porphyria, otosclerosis with hearing impairment, gallbladder disease, cholestasis, jaundice);
• severe depression;
• uterine fibroids;
• Varicose veins;
• combined treatment with anticoagulants;
• hereditary angioedema (possible development or intensification of symptoms of the disease).

Instructions for the use of Femoden: method and dosage

Dragee and Femoden tablets are taken orally according to the order indicated on the package, every day at approximately the same time, washed down with water (a small amount).

Daily dose - 1 pc. for 21 days. Tablets / dragees from the next blister are taken after a break of 7 days. Usually during this period, withdrawal bleeding is observed, as a rule, developing 2-3 days after taking the last pill / dragee and continuing until the start of taking the tablets / dragees from a new package.

If in the previous month the patient did not take any hormonal contraceptives, Femoden is taken on the first day of menstrual bleeding. It is possible to start taking it on days 2-5 of the menstrual cycle, but in this case it is important to additionally use a barrier method of contraception during the first 7 days of taking pills / dragees from the first blister.

Start taking Femoden in cases of switching from a contraceptive patch, vaginal ring, contraceptives containing only gestagens (implant, injectable forms, mini-pills), from an intrauterine contraceptive that releases a gestagen (Mirena), or other combined oral contraceptives:

• patch / ring: on the day of removal or no later than the day when it was planned to stick a new patch / insert a new ring;
• combined oral contraceptives: the next day after taking the last hormone-containing pill from the previous package, but no later than the next day after the usual 7-day break for drugs with 21 pcs. in the package or after taking the last inactive tablet for funds with 28 pcs. packaged;
• mini-drank: any day, without a break;
• implant or intrauterine contraceptive with gestagen: on the day of removal;
• injectable form: from the day the next injection was planned.

In all cases of transition, it is important to additionally use a barrier method of contraception during the first 7 days of taking Femoden.

Patients after an abortion in the first trimester of pregnancy can start taking the drug immediately, and no additional contraceptive protection is required.

Reception of Femoden after an abortion in the second trimester of pregnancy or childbirth begins on the 21-28th day after the abortion or childbirth, if the woman is not breastfeeding. At a later start of taking the drug, it is important to additionally use a barrier method of contraception during the first 7 days of administration. In cases where a woman has already had a sex life, it is required to exclude pregnancy or wait for the first menstruation before taking the pills / dragees.

Contraceptive protection does not decrease if tablets / dragees are missed when the delay is <12 hours. The next tablet / dragee should be taken as soon as possible at the usual time.

If you are late> 12 hours, contraceptive protection may be reduced. The more tablets / pills are missed, and the closer this pass is to a break of 7 days, the higher the likelihood of pregnancy. Based on this, it is recommended not to interrupt Femoden's reception for a period exceeding 7 days. To achieve adequate suppression of hypothalamic-pituitary-ovarian regulation, it is required to take the drug continuously for 7 days.

Recommendations for using Femoden after a break in the first, second or third week of admission:

• first week of admission: the last missed pill / dragee is taken as soon as possible, even if this means taking 2 pieces at the same time The next pill / dragee is taken as usual, and over the next 7 days, a barrier method of contraception is additionally used. It is important to take into account the likelihood of pregnancy if intercourse took place during the week before the pill / dragee was missed
• second week of admission: the last missed pill / dragee is taken as soon as possible, even if this requires simultaneous administration of 2 pcs. The next tablet / tablet is taken as usual. The use of additional contraceptive measures is not necessary in cases when the drug was taken correctly within 7 days preceding the missed first tablet / tablet. If the patient did not take Femoden correctly or 2 or more pills / pills were missed, it is important to use barrier methods of contraception within 7 days;
• third week of admission: due to the upcoming interruption in taking the drug, the risk of reducing its reliability is inevitable. In this case, adhere to one of two options, while, if within 7 days preceding the first missed pill / dragee, Femoden was taken correctly, there is no need to use additional contraceptive methods. The first option is to take the last missed pill / dragee as soon as possible, even if it means taking 2 pcs. at the same time, the next tablets / dragees are taken as usual until the current blister runs out. Taking pills / dragees from the next blister begins immediately. In this case, withdrawal bleeding is unlikely until the pills / dragees from the second blister run out, however, the development of spotting bleeding and breakthrough bleeding from the vagina is possible. The second option is to cancel taking pills / pills from the current blister, take a break of 7 days, including counting the day of the pass, and then start taking pills / pills from a new blister.

In cases where there is a missed pill / dragee intake, and during a break in bleeding, withdrawal is not observed, it is required to exclude pregnancy.

With the development of diarrhea or vomiting within 4 hours after taking Femoden, its absorption may be incomplete, therefore it is important to take additional contraceptive measures and be guided by recommendations when skipping tablets / dragees.

If it is necessary to delay the onset of menstrual bleeding, taking pills or Femoden pills from a new blister continues without interruption immediately after all pills / pills from the previous one have been taken. Tablets / dragees from a new blister can be taken as long as the patient wishes, up to their end. When taking the drug from the second blister, breakthrough uterine bleeding or spotting spotting may occur. Resume taking Femoden from a new blister after the usual 7-day break.

If it is necessary to postpone the day of the onset of menstrual bleeding to another day of the week, shorten the next break in taking pills / dragees by the number of days that is necessary. The shorter the interval, the higher the risk of no withdrawal bleeding and the development of further spotting bleeding and breakthrough bleeding from the vagina during the period of taking the pills / dragees from the second blister (as in the case when the onset of menstrual bleeding is needed to be delayed).

Side effects

Possible adverse reactions (> 10% - very common;> 1% and 0.1% and 0.01% and <0.1% - rarely; <0.01% - very rare).

Film-coated tablets

• organ of vision: rarely - intolerance to contact lenses (discomfort when wearing them), blurred vision;
• gastrointestinal tract: often - abdominal pain, nausea; infrequently - diarrhea, vomiting;
• immune system: rarely - hypersensitivity;
• general symptoms: often - weight gain; rarely - weight loss;
• metabolism: infrequently - fluid retention;
• nervous system: often - headache; infrequently - migraine;
• mental disorders: often - swings or decreased mood; infrequently - decreased libido; rarely - increased libido;
• reproductive system, mammary glands: often - engorgement, pain or tenderness of the mammary glands; infrequently - mammary gland hypertrophy; rarely - discharge from the mammary glands, vaginal discharge;
• skin and subcutaneous tissues: infrequently - urticaria, rash; rarely - erythema multiforme, erythema nodosum.

There are also reports of the development of the following side effects while taking combined oral contraceptives: chloasma, impaired liver function, glucose tolerance or the effect on peripheral insulin resistance, benign and malignant liver tumors, hypertriglyceridemia, increased blood pressure, cerebrovascular disorders, arterial / venous disorders, onset or worsening of conditions for which the connection with the use of combined oral contraceptives has not been proven (cervical cancer, ulcerative colitis, Crohn's disease, hearing loss associated with otosclerosis, herpes during pregnancy, Sydenham's chorea, hemolytic uremic syndrome, systemic red lupus, porphyria, cholelithiasis, jaundice and / or pruritus associated with cholestasis).

Dragee

• digestive system: sometimes - vomiting, nausea;
• reproductive system: sometimes - changes in vaginal secretion, intermenstrual bleeding;
• endocrine system: sometimes - changes in libido, changes in body weight, engorgement, soreness and secretion from the mammary glands;
• central nervous system: migraine, headaches, decreased mood;
• others: allergic reactions, fluid retention in the body, poor tolerance of contact lenses, chloasma.

Overdose

The main symptoms: metrorrhagia or spotting spotting, vomiting, nausea.

Therapy: symptomatic treatment.

special instructions

The ongoing epidemiological studies have shown a relationship between the use of combined oral contraceptives and an increase in the incidence of arterial / venous thrombosis and thromboembolism (cerebrovascular disorders, myocardial infarction, pulmonary embolism, deep vein thrombosis). These pathologies are rare.

In the first year of taking drugs of this group, the risk of developing venous thromboembolism is maximum.

An increased risk is present after the initial intake of drugs of this group or resumption of the use of the same or different drugs (after a break between doses of the drug of 28 days or more) This increased risk is predominantly present during the first 3 months in a large prospective study involving 3 patient groups.

The overall risk of venous thromboembolism in women receiving low-dose combined oral contraceptives is 2–3 times higher than in non-pregnant women who are not receiving such drugs. However, this risk remains lower compared to that of pregnancy and childbirth.

In 1–2% of cases, venous thromboembolism can be fatal.

Taking any combined oral contraceptive pill can cause venous thromboembolism, manifested as pulmonary embolism or deep vein thrombosis.

In extremely rare cases, while taking combined oral contraceptives, thrombosis of other blood vessels develops (renal, mesenteric, hepatic, cerebral veins and arteries, retinal vessels). There is no consensus regarding the relationship between the occurrence of these events with the intake of drugs in this group.

Symptoms of deep vein thrombosis include redness or discoloration of the skin on the lower limb, localized fever in the affected lower limb, discomfort or pain in the lower limb only when walking or standing upright, pain or discomfort, unilateral swelling of the lower limb or along a vein on lower limb.

Symptoms of pulmonary embolism include rapid or irregular heartbeat, severe dizziness, anxiety, sharp chest pain that may worsen with a deep breath, sudden coughing, including hemoptysis, difficulty breathing or rapid breathing. Some of the symptoms (for example, cough and shortness of breath) are nonspecific and can be interpreted as signs of other more or less severe complications (for example, a respiratory tract infection).

Arterial thromboembolism can result in myocardial infarction, vascular occlusion, or stroke. Symptoms of these conditions include:

• stroke: loss of consciousness or fainting with or without an epileptic seizure, sudden, severe or prolonged headache for no apparent reason, loss of balance or coordination of movements, dizziness, sudden gait disturbance, sudden unilateral or bilateral loss of vision, problems with speech and understanding, sudden Confusion, sudden weakness or loss of feeling in a leg, arm, or face, especially on one side of the body;
• vascular occlusion: acute abdomen, slight blue discoloration of the limbs, swelling, sudden pain;
• myocardial infarction: rapid or irregular heartbeat, anxiety or shortness of breath, severe weakness, nausea, vomiting or dizziness, cold sweat, discomfort radiating to the stomach, arm, larynx, cheekbone, back, feeling of tightness or fullness in the arm, chest or behind the breastbone, heaviness, pressure, discomfort, pain.

With arterial thromboembolism, death is possible.

Factors that increase the risk of developing venous and / or arterial thrombosis are:

• age;
• smoking (with an increase in the number of cigarettes or an increase in age, the risk increases, especially in patients over 35 years old);
• a family history of, for example, venous or arterial thromboembolism in parents or close relatives at a relatively young age. With an acquired or hereditary predisposition, an examination by an appropriate specialist is necessary in order to resolve the issue of the possibility of taking combined oral contraceptives;
• dyslipoproteinemia;
• obesity (body mass index> 30 kg per 1 m ²);
• atrial fibrillation;
• heart valve pathology;
• arterial hypertension;
• migraine;
• extensive trauma, any operation on the lower extremities, major surgical intervention, prolonged immobilization. It is advisable in such cases to cancel combined oral contraceptives (with a planned operation at least 28 days before it) and not resume taking them within 14 days after the end of immobilization.

Until now, the question of the role of superficial thrombophlebitis and varicose veins in the development of venous thromboembolism remains controversial.

In the postpartum period, there is an increased risk of thromboembolism. With sickle cell anemia, chronic inflammatory bowel disease, hemolytic uremic syndrome, systemic lupus erythematosus, and diabetes mellitus, peripheral circulatory disorders may also occur.

An increase in the frequency and severity of migraine during the period of taking combined oral contraceptives is the basis for their immediate cancellation.

Biochemical indicators indicating a hereditary or acquired predisposition to arterial / venous thrombosis are antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies), lack of antithrombin III, protein C or S, hyperhomocysteinemia, resistance to activated protein C.

It is important to take into account in assessing the balance between benefits and risks that adequate therapy for the condition can reduce the associated risk of thrombosis. It is equally important to take into account that the risk of thrombosis and thromboembolism during pregnancy is higher than with the use of low-dose oral contraceptives.

Persistent human papillomavirus infection is the most significant risk factor for cervical cancer. There are reports of a slight increase in this risk with prolonged use of combined oral contraceptives. The connection with the use of such funds has not been proven. Controversy persists as to the extent to which these findings are associated with screening for cervical disease or with features of sexual behavior (less frequent use of barrier methods of contraception).

A meta-analysis of 54 epidemiological studies showed the presence of a slightly increased relative risk of developing breast cancer, which was diagnosed in patients currently receiving combined oral contraceptives. Over the 10 years after discontinuation of these drugs, the increased risk gradually disappears. Since, in rare cases, breast cancer occurs in patients under the age of 40, the increase in the number of diagnoses of "breast cancer" while taking combined oral contraceptives, currently or recently, is insignificant in relation to the overall risk of this disease. The connection of pathology with the use of such drugs has not been proven. The observed increase in risk may also be a consequence of an earlier diagnosis of the disease in patients taking combined oral contraceptives. Women who have ever taken these drugs have breast cancer diagnosed earlier than women who have never taken them.

Rarely, while taking combined oral contraceptives, the development of benign, and extremely rarely, malignant liver tumors was noted, which in some cases led to life-threatening intra-abdominal bleeding. If the patient has severe abdominal pain, enlarged liver, or signs of intra-abdominal bleeding, it is important to take this into account when making a differential diagnosis.

With hypertriglyceridemia or a family history of hypertriglyceridemia, the risk of developing pancreatitis may increase while taking combined oral contraceptives.

Many patients, while using combined oral contraceptives, showed a slight increase in blood pressure, and in rare cases, clinically significant increases were observed. However, if there is a persistent, clinically significant increase in blood pressure during the period of taking such drugs, it is important to immediately discontinue these drugs and begin therapy for arterial hypertension. In the future, the resumption of taking combined oral contraceptives is possible when normal blood pressure values are reached.

According to reports, conditions that develop or worsen both during pregnancy and when taking combined oral contraceptives (the connection with the use of such drugs has not been proven) include: hearing loss associated with otosclerosis, herpes (during pregnancy), Sydenham's chorea, hemolytic uremic syndrome, systemic lupus erythematosus, porphyria, gallstones, cholestasis-associated pruritus and / or jaundice, Crohn's disease, ulcerative colitis.

The intake of exogenous estrogens in patients with hereditary forms of angioedema may cause the development or worsening of symptoms of angioedema.

In case of chronic or acute liver pathologies, it may be necessary to cancel combined oral contraceptives until the organ indicators return to normal. Recurrent cholestatic jaundice, which develops for the first time against the background of pregnancy or previous use of sex hormones, requires discontinuation of the drug in this group.

Despite the fact that combined oral contraceptives can affect glucose tolerance and insulin resistance, there is no need to change the therapeutic regimen in patients with diabetes mellitus taking low-dose combined oral contraceptives. However, for such women during the period of taking these funds, careful monitoring is required.

In some cases, chloasma may develop, especially in patients with a history of chloasma in pregnant women. During the period of taking Femoden, women with a tendency to chloasma are advised to avoid exposure to ultraviolet radiation and prolonged exposure to the sun.

The use of combined oral contraceptives may affect the results of some laboratory tests, including the parameters of fibrinolysis, clotting, indicators of carbohydrate metabolism, adrenal, thyroid, kidney or liver function, the concentration of transport proteins in plasma. Usually, changes do not go beyond the normal range.

The effectiveness of the drug can be reduced in cases of diarrhea or vomiting, as a result of drug interactions, or when you skip taking tablets / dragees.

When taking Femoden, irregular bleeding may occur (breakthrough bleeding or spotting spotting), especially during the first months of use. In this regard, the assessment of any irregular bleeding is carried out only after the adaptation period, which is approximately 3 cycles.

Careful examination to rule out malignant neoplasms or pregnancy is required if irregular bleeding recurs or develops after previous regular cycles.

In some cases, withdrawal bleeding may not occur during a break in taking pills / tablets. If the drug is taken as directed, the chance of pregnancy is low. However, if before this the remedy was taken irregularly or two consecutive withdrawal bleeding does not develop, it is recommended to exclude pregnancy before continuing to take Femoden.

It is important to familiarize yourself with the patient's medical history in detail before starting or resuming Femoden's reception, to conduct a gynecological and physical examination. The nature and frequency of these examinations should be based on the existing standards of medical practice, taking into account the individual characteristics of each patient, but at least once every six months, and should include an assessment of the state of the mammary glands, abdominal organs and small pelvis (including cytological examination of the cervical epithelium uterus, blood pressure measurement).

Patients should be aware that taking Femoden does not protect against the human immunodeficiency virus (acquired immunodeficiency syndrome) and other sexually transmitted diseases.

Application during pregnancy and lactation

Femoden is contraindicated for use during pregnancy and lactation.

Despite the fact that numerous epidemiological studies have not revealed any increased risk of developing defects in children whose mothers received sex hormones before pregnancy, or teratogenic effects when accidentally taking sex hormones in early pregnancy, when pregnancy occurs during the period of taking Femoden tablets / dragees immediately cancel.

Taking the drug can change the composition and reduce the amount of breast milk, so its use is not recommended during lactation. In small amounts, sex hormones and / or their metabolites can be excreted in breast milk.

Femoden can be taken only after the onset of menarche.

For violations of liver function

Femoden is contraindicated in patients with malignant or benign liver tumors at present or in history, severe liver pathologies or liver failure.

Use in the elderly

Femoden is not used in elderly patients, since it is not indicated after menopause.

Drug interactions

The result of the interaction of Femoden with other drugs may be breakthrough bleeding and / or a decrease in contraceptive effectiveness. Patients receiving such combinations should temporarily use barrier methods of contraception in addition to Femoden or choose another method of contraception.

With the combined use of Femoden with inducers of microsomal liver enzymes (rifampicin, carbamazepine, primidone, barbiturates, phenytoin; presumably - griseofulvin, felbamate, topiramate, oxcarbazepine, preparations containing St. John's wort), an increase in the clearance of sex hormones is possible. A potential increase in hepatic metabolism is also possible when combined with HIV protease inhibitors (ritonavir) and non-nucleoside reverse transcriptase inhibitors (nevirapine) and their combinations. In cases of taking such funds and within 28 days after their cancellation, it is recommended to additionally use a barrier method of contraception.

Taking some antibacterial drugs (for example, tetracyclines and penicillins) can reduce intestinal-hepatic estrogen recirculation, which reduces the concentration of ethinyl estradiol. When taking antibacterial drugs and within 7 days after their cancellation, you should additionally use a barrier method of contraception. If the period of using the barrier method of contraception ends later than the tablets in the blister, you need to switch to the next pack of Femoden without the usual break.

With the simultaneous use of oral combined contraceptives can affect the metabolism of other drugs, which leads to a decrease (for example, lamotrigine) or an increase (for example, cyclosporine) their concentration in plasma and tissues.

Analogs

The analogues of Femoden are: Femiss Ginesta, Logest, Lindinet 20, Lindinet 30, Gestarella.

Terms and conditions of storage

Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Femoden

According to reviews, Femoden is a reliable, effective, easy-to-use combined contraceptive drug that normalizes the menstrual cycle and hormones and improves the condition of nails, skin and hair. Among the disadvantages, they mainly note the high cost of the drug, the development of side effects in the form of headaches, depression and weight gain while taking it.

Price for Femoden in pharmacies

The approximate price of Femoden in the form of film-coated tablets (21 pcs. Per pack) is 780 rubles, in the form of pills (21 pcs. Per pack) - 696-844 rubles.

Femoden: prices in online pharmacies

Drug name Price Pharmacy

Femoden film-coated tablets 21 pcs. RUB 680 Buy

Femoden tablets p.p. 75μg + 30μg 21 pcs. 730 RUB Buy

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!